- Home
- NTAP vs BIIB Comparison
NTAP vs BIIB Comparison
Compare NTAP & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NTAP
- BIIB
- Stock Information
- Founded
- NTAP 1992
- BIIB 1978
- Country
- NTAP United States
- BIIB United States
- Employees
- NTAP N/A
- BIIB N/A
- Industry
- NTAP Electronic Components
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- NTAP Technology
- BIIB Health Care
- Exchange
- NTAP Nasdaq
- BIIB Nasdaq
- Market Cap
- NTAP 24.9B
- BIIB 25.1B
- IPO Year
- NTAP 1995
- BIIB 1991
- Fundamental
- Price
- NTAP $130.31
- BIIB $159.34
- Analyst Decision
- NTAP Buy
- BIIB Buy
- Analyst Count
- NTAP 19
- BIIB 25
- Target Price
- NTAP $135.94
- BIIB $258.57
- AVG Volume (30 Days)
- NTAP 2.2M
- BIIB 1.6M
- Earning Date
- NTAP 11-21-2024
- BIIB 10-30-2024
- Dividend Yield
- NTAP 1.61%
- BIIB N/A
- EPS Growth
- NTAP 69.33
- BIIB 10.05
- EPS
- NTAP 5.44
- BIIB 11.06
- Revenue
- NTAP $6,473,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- NTAP $8.10
- BIIB N/A
- Revenue Next Year
- NTAP $5.45
- BIIB N/A
- P/E Ratio
- NTAP $23.69
- BIIB $14.41
- Revenue Growth
- NTAP 6.10
- BIIB N/A
- 52 Week Low
- NTAP $83.62
- BIIB $153.62
- 52 Week High
- NTAP $135.45
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- NTAP 60.72
- BIIB 35.55
- Support Level
- NTAP $121.91
- BIIB $158.31
- Resistance Level
- NTAP $130.24
- BIIB $162.62
- Average True Range (ATR)
- NTAP 3.96
- BIIB 3.00
- MACD
- NTAP 0.73
- BIIB 1.00
- Stochastic Oscillator
- NTAP 68.52
- BIIB 48.60
About NTAP NetApp Inc.
NetApp Inc is a provider of enterprise data management and storage solutions. The company's segments include Hybrid Cloud and Public Cloud. It generates maximum revenue from the Hybrid Cloud segment. The Hybrid Cloud segment offers a portfolio of storage management and infrastructure solutions that help customers recast their traditional data centers with the power of cloud. This portfolio is designed to operate with public clouds to unlock the potential of hybrid, multi-cloud operations. Hybrid Cloud is composed of software, hardware, and related support, as well as professional and other services.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.